Insulin pump therapy in childhood diabetes mellitus: Guidelines for use

Treatments in Endocrinology

Volumn 2, Issue 1, 2003, Pages 11-21

  Tamborlane, William V ^a,b   Fredrickson, Linda P ^a   Ahern, JoAnn H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDTRONIC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; ELA MAX; EMLA; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; LIDOCAINE;

ALGORITHM; BLOOD GLUCOSE MONITORING; CHILD; CHILDHOOD DISEASE; DAY CARE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC KETOACIDOSIS; DRUG EFFICACY; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; NURSERY; PATIENT CARE; PATIENT EDUCATION; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHOOL; SELF MONITORING; SPORT; WEIGHT GAIN;

ADOLESCENT; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; EXERCISE; HUMANS; HYPOGLYCEMIA; INSULIN INFUSION SYSTEMS; PATIENT CARE TEAM; PATIENT SELECTION; SCHOOL HEALTH SERVICES; TREATMENT OUTCOME;

EID: 0042360244     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200302010-00002     Document Type: Review

References (36)

1. Tamborlane WV, Sherwin RS, Genel M, et al. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979; 300: 573-8
2. Pickup JC, Keen H, Parsons JA, et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. BMJ 1978; 1: 204-7
3. Lauritzen T, Pramming S, Deckert T, et al. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983; 24: 326-9
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
5. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and long-term complications in adolescents with insulin-dependent diabetes mellitus. J Pediatr 1994; 125: 177-88
6. DCCT/EDIC Research Group. Prolonged beneficial effects of intensive therapy of diabetes during adolescence: microvascular outcomes four years after conclusion of the Diabetes Control and Complications Trial. J Pediatr 2001; 139: 804-12
7. The Diabetes Control and Complications Trial Research Group. Resource utilization and costs of care in the diabetes control and complications trial. Diabetes Care 1995; 18: 1468-78
8. Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion: a "new" way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22: 1779-84
9. Zinman B, Tildesley H, Chiasson J-L, et al. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997; 46: 440-3
10. Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28),Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402
11. Ahern JAH, Boland EA, Doane R, et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatric Diabetes 2002; 3: 10-5
12. de Beaufort CE, Houtzagers CMGJ, Bruining GJ, et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: two-year follow-up of a randomized, prospective trial. Diabet Med 1989; 6: 766-71
13. Tubiana-Rufi N, deLonlay P, Block J, et al. Remission of severe hypoglycemia incidents in young diabetic children treated with subcutaneous infusion. Arch Pediatr 1996; 3: 969-76
14. Buckingham BA, Paguntalan H, Fassl B, et al. Continuous subcutaneous insulin infusion (CSII) in children under five years of age [abstract]. Diabetes 2001; 50 Suppl. 2: A107
15. Maniatis AK, Klingensmith GJ, Slover RH, et al. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 2001; 107: 351-6
16. White NH, Hollander AS, Sadler M, et al. Risks and benefits of continuous subcutaneous insulin infusion (CSII) therapy in children [abstract]. Diabetes 2001; 50 Suppl. 2: A66
17. Celona-Jacobs N, Weinzimer SA, Rearson M, et al. Insulin pump therapy in children: a cautionary tale [abstract]. Diabetes 2001; 50 Suppl. 2: A67
18. Laffel L, Loughlin C, Ramchandani N, et al. Glycemic challenges of pump therapy (CSII) in youth with type 1 diabetes (T1DM) [abstract]. Diabetes 2001; 50 Suppl. 2: A66
19. Steindel BS, Roe TR, Costin G, et al. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diabetes Res Clin Pract 1995; 27: 199-204
20. Kaufman FR, Kim C, Halvorson M, et al. Use of insulin pump therapy at nighttime only for children 7-10 years of age with type 1 diabetes. Diabetes Care 2000; 23: 579-82
21. Kaufman FR, Halvorson M, Carpenter S, et al. Insulin pump therapy in young children with diabetes. Diabetes Spectrum 2001; 14: 84-9
22. Boland E. Teens pumping it up. 2nd ed. Sylmar (CA): MiniMed, 1998
23. Kaufman FR, Halvorson M, Miller D, et al. Insulin pump therapy in type 1 pediatric patients: now and into the year 2000. Diabetes Metab Res Rev 1999; 15: 338-52
24. Fredrickson F, Rubin RR, Rubin S. Optimal pumping: a guide to good health with diabetes. Northridge (CA): MiniMed Inc, 2001
25. Ahern JA, Ramchandani N, Cooper J, et al. Using a primary nurse manager to implement DCCT recommendations in a large pediatric program. Diabetes Educ 2000; 26: 990-4
26. Boland EA, Ahern JH, Ahern JA, et al. Pumps and kids: basal requirements for excellent metabolic control [abstract]. Diabetes 2002; 51 Suppl. 2: A11
27. Ahern JA, Gatcomb PM, Held NA, et al. Exaggerated hyperglycemia after a pizza meal in well-controlled diabetes. Diabetes Care 1993; 16: 578-80
28. Grey M, Boland EA, Davidson M, et al. Coping skills training for youth with diabetes mellitus has long-lasting effects on metabolic control and quality of life. J Pediatr 2000; 137: 107-13
29. Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause [abstract]. Diabetes Care 2001; 24: 174
30. Attia N, Jones TW, Holcombe J, et al. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 1998; 21: 817-21
31. Davis EA, Keating B, Byrne GC, et al. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 1997; 20: 22-5
32. Garg SK, Potts RO, Ackerman NR, et al. Correlation of fingerstick blood glucose measurements with GlucoWatch Biographer glucose results in young subjects with type 1 diabetes. Diabetes Care 1999; 22: 1708-14
33. Boland E, Monsod T, DeLucia M, et al. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from three days of continuous glucose sensing in pediatric patients with type I diabetes. Diabetes Care 2001; 24: 1858-62
34. Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care 2001; 24: 2030-4
35. Bode BW, Gross TM, Thornton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract 1999; 46: 183-90
36. Albisser AM, Leibel BS, Ewart TG, et al. Clinical control of diabetes by the artificial pancreas. Diabetes 1974; 23: 397-404